Patent ID: 9266872
Filing Date: 2016-02-23
CPC Classification: A61K,A61P,C07D

Claim Text:
1. A method for inhibiting colorectal cancer metastasis comprising: administrating a pharmaceutically effective dose of a 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof, wherein the 2-hydroxyarylamide derivative is selected from the group consisting of: (6) 5-chloro-2-hydroxy-N-(3-methoxy-5-(trifluoromethyl)phenyl)benzamide; (19) 5-chloro-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-hydroxybenzamide; (25) 5-chloro-2-hydroxy-N-quinoline-3-yl-benzamide; (27) 5-chloro-N-(2-chloro-4-cyano-phenyl)-2-hydroxy-benzamide; (28) 5-chloro-2-hydroxy-N-(5-trifluoromethyl-[1,3,4]thiadiazole-2-yl)-benzamide; (32) 5-chloro-N-(4-chloro-3-(trifluoromethyl)phenyl)-2-hydroxybenzamide; (36) 5-chloro-2-hydroxy-N-(2-nitro-4-trifluoromethyl-phenyl)-benzamide; (37) 5-chloro-N-(5-cyano-pyridine-2-yl)-2-hydroxy-benzamide; and (53) 5-chloro-2-hydroxy-N-(4-phenylthiazole-2-yl)benzamide; wherein the 2-hydroxyarylamide derivative or a pharmaceutically acceptable salt thereof inhibits the activity of TMPRSS4 (transmembrane protease serine-4).